Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,173,000 | 2,527,000 | 1,225,000 | 5,723,000 | 4,129,000 |
| Depreciation Amortization | 2,411,000 | 1,610,000 | 805,000 | 3,243,000 | 2,430,000 |
| Accounts receivable | -533,000 | -476,000 | -151,000 | -356,000 | -424,000 |
| Other Working Capital | -826,000 | -989,000 | -561,000 | -2,475,000 | -951,000 |
| Other Operating Activity | 465,000 | 313,000 | -293,000 | 1,126,000 | -961,000 |
| Operating Cash Flow | $5,690,000 | $2,985,000 | $1,025,000 | $7,261,000 | $4,223,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 9,000 | 49,000 | -28,000 | N/A | -45,000 |
| PPE Investments | -1,487,000 | -931,000 | -398,000 | -2,202,000 | -1,447,000 |
| Net Acquisitions | 1,000 | 1,000 | N/A | -837,000 | -837,000 |
| Purchase Of Investment | N/A | N/A | N/A | -159,000 | N/A |
| Sale Of Investment | N/A | N/A | N/A | 43,000 | N/A |
| Other Investing Activity | 5,000 | 3,000 | 1,000 | 22,000 | 20,000 |
| Investing Cash Flow | $-1,472,000 | $-878,000 | $-425,000 | $-3,133,000 | $-2,309,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -126,000 | -170,000 | -127,000 | 21,000 | -90,000 |
| Debt Issued | 222,000 | 221,000 | 0 | 2,000 | 1,000 |
| Debt Repayment | -20,000 | -18,000 | 0 | -2,498,000 | -1,447,000 |
| Common Stock Issued | 239,000 | 147,000 | 134,000 | 167,000 | 133,000 |
| Common Stock Repurchased | -980,000 | -229,000 | -226,000 | -1,227,000 | -968,000 |
| Dividend Paid | -2,878,000 | -1,918,000 | -957,000 | -3,556,000 | -2,668,000 |
| Financing Cash Flow | $-3,543,000 | $-1,967,000 | $-1,176,000 | $-7,091,000 | $-5,039,000 |
| Exchange Rate Effect | -13,000 | -49,000 | -36,000 | -23,000 | -48,000 |
| Beginning Cash Position | 6,896,000 | 6,896,000 | 6,896,000 | 9,882,000 | 9,882,000 |
| End Cash Position | 7,558,000 | 6,987,000 | 6,284,000 | 6,896,000 | 6,709,000 |
| Net Cash Flow | $662,000 | $91,000 | $-612,000 | $-2,986,000 | $-3,173,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 5,690,000 | 2,985,000 | 1,025,000 | 7,261,000 | 4,223,000 |
| Capital Expenditure | -1,487,000 | -931,000 | -398,000 | -2,202,000 | -1,447,000 |
| Free Cash Flow | 4,203,000 | 2,054,000 | 627,000 | 5,059,000 | 2,776,000 |